VolitionRx Receives Acceptance of Compliance Plan from NYSE American
VolitionRx Limited (VNRX) has received approval from NYSE American for its compliance plan to meet listing standards. The company was previously notified of non-compliance due to insufficient stockholders' equity and ongoing losses. The plan aims to regain compliance by August 6, 2027.
Topics: equity requirements financial reporting listing standards NYSE American stock compliance